Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 874219-27-9 | MDL No. : | MFCD08235046 |
Formula : | C9H11BFNO3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | CRXFXVKQLCHKSK-UHFFFAOYSA-N |
M.W : | 211.00 | Pubchem ID : | 44717542 |
Synonyms : |
|
Num. heavy atoms : | 15 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.22 |
Num. rotatable bonds : | 3 |
Num. H-bond acceptors : | 4.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 54.12 |
TPSA : | 60.77 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -7.31 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 0.39 |
Log Po/w (WLOGP) : | -0.37 |
Log Po/w (MLOGP) : | 0.53 |
Log Po/w (SILICOS-IT) : | -0.83 |
Consensus Log Po/w : | -0.06 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.49 |
Solubility : | 6.8 mg/ml ; 0.0322 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.23 |
Solubility : | 12.4 mg/ml ; 0.0586 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -1.63 |
Solubility : | 4.9 mg/ml ; 0.0232 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.98 |
Signal Word: | Warning | Class: | |
Precautionary Statements: | P261-P264-P271-P280-P302+P352-P304+P340+P312-P305+P351+P338-P332+P313-P337+P313-P362-P403+P233-P405-P501 | UN#: | |
Hazard Statements: | H315-H319-H335 | Packing Group: | |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Stage #1: 6-bromo-2-[2-(3,5-dimethoxyphenyl)ethyl]-5H-pyrrolo[2,3-b]pyrazine; 3-(dimethylcarbamoyl)-4-fluorophenylboronic acid With bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II); sodium carbonate In 1,4-dioxane; water at 110℃; Inert atmosphere; Stage #2: trifluoroacetic acid In 1,4-dioxane; water | 54 Step 2. 2-Chloro-4-(2-(3,5-dimethoxyphenethyl)-5H-pyrrolo[2,3-b]pyrazin-6-yl)-N-isopropylbenzamide General procedure: A mixture of 6-bromo-2-[2-(3,5-dimethoxyphenyl)ethyl]-5H-pyrrolo[2,3-b]pyrazine (10.0 mg, 0.0276 mmol), 2-chloro-N-isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (13.0 mg, 0.041 mmol, from Combi-Blocks), sodium carbonate (5.8 mg, 0.055 mmol) and dichloro(bis{di-tert-butyl[4-(dimethylamino)phenyl]phosphoranyl})palladium (0.59 mg, 0.00083 mmol) in 1,4-dioxane (0.5 mL)/water (0.1 mL) was evacuated and refilled with N2 three times. The reaction was then stirred at 110 °C. overnight. The mixture was purified by RP-HPLC (pH=2, TFA as the media) to afford the desired product as TFA salt. LCMS calculated for C26H28ClN4O3 (M+H)+: m/z=479.2. Found 479.1. The compound was prepared by using procedure analogous to those described for the synthesis of Example 53, Step 2 starting from 6-bromo-2-[2-(3,5-dimethoxyphenyl)ethyl]-5H-pyrrolo[2,3-b]pyrazine and 3-(dimethylcarbamoyl)-4-fluorophenylboronic acid (from Combi-Blocks). LCMS calculated for C25H26FN4O3 (M+H)+: m/z=449.2. Found 449.1. |
[ 874289-13-1 ]
(4-(Dimethylcarbamoyl)-3-fluorophenyl)boronic acid
Similarity: 0.98
[ 874219-28-0 ]
(3-(Diethylcarbamoyl)-4-fluorophenyl)boronic acid
Similarity: 0.97
[ 874219-19-9 ]
(4-Fluoro-3-(methylcarbamoyl)phenyl)boronic acid
Similarity: 0.96
[ 874289-14-2 ]
(4-(Diethylcarbamoyl)-3-fluorophenyl)boronic acid
Similarity: 0.95
[ 874289-13-1 ]
(4-(Dimethylcarbamoyl)-3-fluorophenyl)boronic acid
Similarity: 0.98
[ 874289-13-1 ]
(4-(Dimethylcarbamoyl)-3-fluorophenyl)boronic acid
Similarity: 0.98
[ 874219-28-0 ]
(3-(Diethylcarbamoyl)-4-fluorophenyl)boronic acid
Similarity: 0.97
[ 874219-28-0 ]
(3-(Diethylcarbamoyl)-4-fluorophenyl)boronic acid
Similarity: 0.97
[ 874219-19-9 ]
(4-Fluoro-3-(methylcarbamoyl)phenyl)boronic acid
Similarity: 0.96
[ 874289-13-1 ]
(4-(Dimethylcarbamoyl)-3-fluorophenyl)boronic acid
Similarity: 0.98
[ 874219-28-0 ]
(3-(Diethylcarbamoyl)-4-fluorophenyl)boronic acid
Similarity: 0.97
[ 874219-19-9 ]
(4-Fluoro-3-(methylcarbamoyl)phenyl)boronic acid
Similarity: 0.96
[ 874289-13-1 ]
(4-(Dimethylcarbamoyl)-3-fluorophenyl)boronic acid
Similarity: 0.98
[ 874219-28-0 ]
(3-(Diethylcarbamoyl)-4-fluorophenyl)boronic acid
Similarity: 0.97
[ 874219-19-9 ]
(4-Fluoro-3-(methylcarbamoyl)phenyl)boronic acid
Similarity: 0.96
[ 874289-13-1 ]
(4-(Dimethylcarbamoyl)-3-fluorophenyl)boronic acid
Similarity: 0.98
[ 874219-28-0 ]
(3-(Diethylcarbamoyl)-4-fluorophenyl)boronic acid
Similarity: 0.97
[ 874219-19-9 ]
(4-Fluoro-3-(methylcarbamoyl)phenyl)boronic acid
Similarity: 0.96
[ 874289-14-2 ]
(4-(Diethylcarbamoyl)-3-fluorophenyl)boronic acid
Similarity: 0.95